Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$46.04
+0.2%		$54.26
$20.18
▼
$72.36
$1.37B0.76596,023 shs371,593 shs
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$4.76
+2.5%		$4.76
$0.81
▼
$6.79
$388.29M1.451.61 million shs1.51 million shs
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
$29.04
-1.2%		$33.49
$27.56
▼
$40.71
$1.51B0.81445,673 shs219,725 shs
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
$27.70
+2.2%		$26.85
$21.95
▼
$53.65
$1.51B2.16903,541 shs1.44 million shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
+0.20%-6.42%-14.53%-26.35%+46.76%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
0.00%0.00%0.00%0.00%-0.31%
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-1.19%-1.86%-10.92%-13.24%-10.37%
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
+2.18%+4.81%+12.60%-7.30%+0.98%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$46.04
+0.2%		$54.26
$20.18
▼
$72.36
$1.37B0.76596,023 shs371,593 shs
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$4.76
+2.5%		$4.76
$0.81
▼
$6.79
$388.29M1.451.61 million shs1.51 million shs
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
$29.04
-1.2%		$33.49
$27.56
▼
$40.71
$1.51B0.81445,673 shs219,725 shs
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
$27.70
+2.2%		$26.85
$21.95
▼
$53.65
$1.51B2.16903,541 shs1.44 million shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
+0.20%-6.42%-14.53%-26.35%+46.76%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
0.00%0.00%0.00%0.00%-0.31%
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-1.19%-1.86%-10.92%-13.24%-10.37%
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
+2.18%+4.81%+12.60%-7.30%+0.98%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.71
Moderate Buy$77.7968.95% Upside
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
2.60
Moderate Buy$7.3354.22% Upside
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
2.58
Moderate Buy$56.3894.13% Upside
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
3.08
Buy$63.40128.88% Upside

Current Analyst Ratings Breakdown

Latest IMAB, IMCR, ANAB, and MAZE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$70.00 ➝ $60.00
9/24/2026
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$110.00
9/23/2026
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$50.00
9/23/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$90.00 ➝ $81.00
9/23/2026
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$50.00
9/23/2026
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$48.00
9/22/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$95.00
9/22/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/22/2026
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$46.00
9/21/2026
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/3/2026
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$234.60M5.87N/AN/A$1.34 per share34.36
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/A$2.47 per shareN/A
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
$400.02M3.74N/AN/A$7.52 per share3.86
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
$167.50M9.19N/AN/A$7.38 per share3.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$13.23M$5.378.5719.02N/A82.37%112.00%2.20%11/3/2026 (Estimated)
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$22.23M-$0.36N/AN/AN/AN/A-19.65%-18.58%N/A
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-$35.51M-$0.37N/A116.16N/A-4.20%-4.54%-1.66%11/5/2026 (Estimated)
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
-$131.12M-$2.52N/AN/AN/AN/A-34.94%-30.18%N/A

Latest IMAB, IMCR, ANAB, and MAZE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-$0.1204N/AN/AN/A$152.86 millionN/A
11/3/2026Q3 2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.84N/AN/AN/A$25.56 millionN/A
9/21/2026Q2 2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$0.4650$5.11+$5.5750$5.11$14.06 million$27.49 million
8/11/2026Q2 2026
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
-$0.76-$0.76N/A-$0.76N/AN/A
8/7/2026Q2 2026
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-$0.01-$0.02-$0.01-$0.02$148.57 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/AN/A
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
N/AN/AN/AN/AN/A
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
7.58
7.58
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/A
22.82
22.82
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
0.94
4.47
4.44
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
0.09
18.31
18.31

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38.38%
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
84.50%
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
31.50%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
22.10%
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
10.10%
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10429.90 million20.48 millionOptionable
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38081.66 million63.61 millionOptionable
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
52451.50 million46.30 millionOptionable
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
14155.55 million52.61 millionN/A

Recent News About These Companies

Maze Therapeutics (NASDAQ:MAZE) Shares Climb 4.7% - Still a Buy?
October 12 at 12:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-maze-therapeutics-nasdaq-maze-shares-climb-47-still-a-buy-2026-10-12/
MAZE Stock Gets Increased EPS Forecast from HC Wainwright
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095833
HC Wainwright Issues Optimistic Estimate for MAZE Earnings
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-issues-optimistic-estimate-for-maze-earnings-2026-10-07/
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3376001/0/en/maze-therapeutics-to-present-data-from-mze829-and-mze782-programs-at-asn-kidney-week-2026.html
Maze Therapeutics, Inc. (MAZE) Interactive Stock Chart - Yahoo Finance
October 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/MAZE/chart/
Research Analysts Set Expectations for MAZE Q2 Earnings
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31091259
What is HC Wainwright's Estimate for MAZE Q2 Earnings?
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-what-is-hc-wainwrights-estimate-for-maze-q2-earnings-2026-10-06/
Illustration of dark reflective blocks etched with candlestick stock charts, lit by glowing golden light sources.
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight (MAZE)
...
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/articles/3-small-cap-stocks-with-catalysts-that-could-put-them-in-the-spotlight/
Allogene Therapeutics (NASDAQ:ALLO) and Maze Therapeutics (NASDAQ:MAZE) Financial Analysis
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085307
Maze Therapeutics' CMO Harold Bernstein Executes 16,141 Share Sale via 10b5-1 Plan
October 4, 2026  |  kalkinemedia.comK
Critical Contrast: Fate Therapeutics (NASDAQ:FATE) & Maze Therapeutics (NASDAQ:MAZE)
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084396
Maze Therapeutics Officer Jason V. Coloma Files Form 144 for Proposed Sale of 34,501 Shares
October 3, 2026  |  kalkinemedia.comK
Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 16,141 Shares of Stock
October 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-maze-insider-buying-and-selling-2026-10-03/
Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 34,501 Shares of Stock
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082800
Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Atul Dandekar Sells 7,500 Shares
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082530
Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Harold Bernstein Sells 16,141 Shares
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-maze-therapeutics-nasdaq-maze-stock-insider-harold-bernstein-sells-16141-shares-2026-10-02/
Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Jason Coloma Sells 34,501 Shares
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-maze-therapeutics-nasdaq-maze-stock-insider-jason-coloma-sells-34501-shares-2026-10-02/
Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Company Stock
October 2, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-maze-insider-buying-and-selling-2026-10-02/
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $202,950.00 in Stock
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-maze-therapeutics-nasdaq-maze-insider-sells-20295000-in-stock-2026-10-01/
Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Has Consensus Price Target of $63.40
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-maze-therapeutics-inc-nasdaq-maze-stock-has-consensus-price-target-of-6340-2026-10-01/
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 4.5% - Here's Why
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-maze-therapeutics-nasdaq-maze-stock-price-up-45-heres-why-2026-09-28/

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$46.04 +0.09 (+0.20%)
Closing price 10/12/2026 04:00 PM Eastern
Extended Trading
$46.08 +0.05 (+0.10%)
As of 10/12/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

I-Mab stock logo

I-Mab NASDAQ:IMAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Immunocore stock logo

Immunocore NASDAQ:IMCR

$29.04 -0.35 (-1.19%)
Closing price 10/12/2026 04:00 PM Eastern
Extended Trading
$29.10 +0.06 (+0.21%)
As of 10/12/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Maze Therapeutics stock logo

Maze Therapeutics NASDAQ:MAZE

$27.70 +0.59 (+2.18%)
Closing price 10/12/2026 04:00 PM Eastern
Extended Trading
$27.56 -0.14 (-0.50%)
As of 10/12/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas